Ashwell S[au] - Search Results

Year	Number of Results
1847	1
1854	1
1985	1
1992	1
1993	1
1996	1
1997	1
2000	1
2001	1
2002	1
2004	4
2006	4
2007	2
2008	5
2009	3
2010	3
2011	1
2012	2
2019	1
2020	3
2021	2
2022	1
2024	1

1

Home PD, Ashwell SG. Home PD, et al. Among authors: ashwell sg. Diabetes Metab Res Rev. 2002 Sep-Oct;18 Suppl 3:S57-63. doi: 10.1002/dmrr.317. Diabetes Metab Res Rev. 2002. PMID: 12324987 Review.

2

Climate effects of CaRMS applications.

Ashwell S. Ashwell S. Can Fam Physician. 2021 Apr;67(4):230. doi: 10.46747/cfp.6704230. Can Fam Physician. 2021. PMID: 33853903 Free PMC article. No abstract available.

3

Checkpoint kinase inhibitors: a review of the patent literature.

Janetka JW, Ashwell S. Janetka JW, et al. Among authors: ashwell s. Expert Opin Ther Pat. 2009 Feb;19(2):165-97. doi: 10.1517/13543770802653622. Expert Opin Ther Pat. 2009. PMID: 19441917 Review.

4

Keeping checkpoint kinases in line: new selective inhibitors in clinical trials.

Ashwell S, Janetka JW, Zabludoff S. Ashwell S, et al. Expert Opin Investig Drugs. 2008 Sep;17(9):1331-40. doi: 10.1517/13543784.17.9.1331. Expert Opin Investig Drugs. 2008. PMID: 18694366 Review.

5

The identification and optimization of orally efficacious, small molecule VLA-4 antagonists.

Huryn DM, Konradi AW, Ashwell S, Freedman SB, Lombardo LJ, Pleiss MA, Thorsett ED, Yednock T, Kennedy JD. Huryn DM, et al. Among authors: ashwell s. Curr Top Med Chem. 2004;4(14):1473-84. doi: 10.2174/1568026043387467. Curr Top Med Chem. 2004. PMID: 15544538 Review.

6

Insulin glargine: the first clinically useful extended-action insulin analogue.

Ashwell SG, Home PD. Ashwell SG, et al. Expert Opin Pharmacother. 2001 Nov;2(11):1891-902. doi: 10.1517/14656566.2.11.1891. Expert Opin Pharmacother. 2001. PMID: 11825324 Review.

7

DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy.

Ashwell S, Zabludoff S. Ashwell S, et al. Clin Cancer Res. 2008 Jul 1;14(13):4032-7. doi: 10.1158/1078-0432.CCR-07-5138. Clin Cancer Res. 2008. PMID: 18593978 Review.

8

Microbiological evaluation of resection margins of the infected diabetic foot ulcer.

Macauley M, Adams G, Mackenny P, Kubelka I, Scott E, Buckworth R, Biddiscombe C, Aitkins C, Lake H, Matthews V, Ashraff S, Ashwell S. Macauley M, et al. Among authors: ashwell s. Diabet Med. 2021 Apr;38(4):e14440. doi: 10.1111/dme.14440. Epub 2020 Nov 11. Diabet Med. 2021. PMID: 33113230

9

Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.

Caravella JA, Lin J, Diebold RB, Campbell AM, Ericsson A, Gustafson G, Wang Z, Castro J, Clarke A, Gotur D, Josephine HR, Katz M, Kershaw M, Yao L, Toms AV, Barr KJ, Dinsmore CJ, Walker D, Ashwell S, Lu W. Caravella JA, et al. Among authors: ashwell s. J Med Chem. 2020 Feb 27;63(4):1612-1623. doi: 10.1021/acs.jmedchem.9b01423. Epub 2020 Feb 12. J Med Chem. 2020. PMID: 31971798

10

Note from Dr. Ashwell.

Ashwell S. Ashwell S. Br Foreign Med Rev. 1847 Apr;23(46):612. Br Foreign Med Rev. 1847. PMID: 30162605 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

40 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year